Welcome!

Agile Computing Authors: Liz McMillan, Pat Romanski, Dana Gardner, Elizabeth White, John Esposito

News Feed Item

Express Scripts Reports Third Quarter Results

Raises Full Year Earnings Guidance

ST. LOUIS, Nov. 5, 2012 /PRNewswire/ -- Express Scripts (Nasdaq: ESRX) announced 2012 third quarter net income of $391.4 million, or $0.47 per diluted share.  Adjusted earnings per share, as detailed in Table 4 were $1.02 per diluted share for the third quarter.

"Our solid third quarter results demonstrate our continued success as a combined organization," stated George Paz, chairman and chief executive officer.  "Integration continues on track and together we are building on our legacy of advancing healthcare through innovation and an unwavering alignment with our clients."

Third Quarter 2012 Review (Data reflected on an adjusted basis. See Tables 2 and 3)

All key metrics compared to 2011 were affected by the inclusion of Medco results beginning in the second quarter of 2012.  Gross profit margin and EBITDA per adjusted claim increases over last year are mainly attributed to improved operating performance, including increased generic utilization.

  • Adjusted claims of 398.9 million, up 116% from third quarter 2011  
  • Gross profit of $2.2 billion, up 153% from third quarter 2011
  • Gross profit margin of 8.1% up from 7.5% in third quarter 2011
  • EBITDA of $1.6 billion, up 136% from third quarter 2011
  • EBITDA per adjusted claim of $4.06, up 9% from third quarter 2011
  • Year to date cash flow from operations of $2.0 billion, up 23% from third quarter 2011

2012 Guidance

Due to strong operating performance, increased generic utilization and the accelerated realization of synergies, the Company now expects to achieve adjusted earnings per share for 2012 in the range of $3.65 to $3.75.  Adjusted earnings per share excludes items as detailed in Table 5. 

Total adjusted claims are expected to be approximately 1.4 billion.  The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range.

The successful integration of Medco continues, with the Company meeting or exceeding its targets.

2013 Economic and Environmental Outlook

Express Scripts previously announced that it will provide 2013 guidance in conjunction with its fourth quarter results.  In addition to the expected claims loss from the UnitedHealthcare book of business throughout the year, the Company believes its 2013 outlook will also be influenced by the current weak business climate and the unemployment outlook.  These factors would likely result in significant in-group member attrition, continued low utilization rates and increased client demands and expectations.

Express Scripts expects to grow earnings per share and EBITDA in 2013.  However, given the factors discussed above, the Company views current consensus estimates for 2013 as overly aggressive.

"Despite near-term headwinds and a challenging macroeconomic environment, we remain confident we are well-positioned for continued growth", stated Paz.  "We have historically managed expenses rigorously while investing toward the future, focusing on innovation, service and optimal clinical outcomes, and will continue to do so, even when faced with challenges on other fronts."  

About Express Scripts

Express Scripts manages more than a billion prescriptions each year for tens of millions of people. On behalf of our clients — employers, health plans, unions and government health programs — we make the use of prescription drugs safer and more affordable. We innovate to enhance patient care, reduce pharmacy-related waste and increase therapy adherence. Building on a strong clinical foundation, we apply our understanding of the behavioral sciences — an approach we call Consumerology® — to make it easier for people to choose better health.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit www.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-Q filed with the SEC on or about November 5, 2012.  A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Operations 










 Three Months Ended

September 30, 


 Nine Months Ended

September 30, 

(in millions, except per share data) 

2012


2011


2012


2011









Revenues(1)

$ 26,999.4


$ 11,571.0


$ 66,824.5


$ 34,026.9

Cost of revenues(1)

24,864.9


10,735.2


61,745.1


31,661.5

    Gross profit 

2,134.5


835.8


5,079.4


2,365.4

Selling, general and administrative

1,336.0


230.7


3,220.7


628.6

Operating income

798.5


605.1


1,858.7


1,736.8

Other (expense) income:








    Undistributed gain from joint venture 

5.1


-


9.4


-

    Interest income  

1.4


5.9


6.0


7.8

    Interest expense and other 

(155.9)


(94.3)


(463.1)


(184.3)


(149.4)


(88.4)


(447.7)


(176.5)

Income before income taxes

649.1


516.7


1,411.0


1,560.3

Provision for income taxes

257.7


192.0


602.2


574.9

Net income 

$      391.4


$      324.7


$      808.8


$      985.4









Weighted average number of common shares








 outstanding during the period: 








    Basic 

812.9


487.2


702.4


506.1

    Diluted 

829.6


490.8


718.9


510.3









Basic earnings per share

$        0.48


$        0.67


$        1.15


$        1.95









Diluted earnings per share

$        0.47


$        0.66


$        1.13


$        1.93









(1) Includes retail pharmacy co-payments of $3,348.9 million and $1,390.4 million for the three months ended September 30, 2012 and 2011, respectively and $8,364.6 million and $4,374.0 million for the nine months ended September 30, 2012 and 2011, respectively. 



 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Balance Sheet 






 September 30,  


   December 31, 

 (in millions) 

2012


2011

 Assets 




 Current assets: 




 Cash and cash equivalents 

$          1,248.4


$       5,620.1

 Restricted cash and investments 

47.3


17.8

 Receivables, net 

5,720.3


1,915.7

 Inventories 

1,561.4


374.4

 Deferred taxes 

417.3


45.8

 Prepaid expenses and other current assets 

437.8


84.2

    Total current assets 

9,432.5


8,058.0

 Property and equipment, net 

1,710.2


416.2

 Goodwill 

29,367.5


5,485.7

 Other intangible assets, net 

16,735.9


1,620.9

 Other assets 

61.6


26.2

    Total assets 

$        57,307.7


$     15,607.0





 Liabilities and Stockholders' Equity 




 Current liabilities: 




 Claims and rebates payable 

$          6,710.0


$       2,874.1

 Accounts payable 

2,139.4


928.1

 Accrued expenses 

1,964.9


656.0

 Short-term loan payable 

40.0


-

 Current maturities of long-term debt 

938.6


999.9

    Total current liabilities 

11,792.9


5,458.1

 Long-term debt 

16,146.3


7,076.4

 Other liabilities 

6,623.6


598.8

    Total liabilities 

34,562.8


13,133.3





 Stockholders' Equity: 




 Preferred stock, 15.0 shares authorized, $0.01 par value per share;   



 and no shares issued and outstanding 

-


-

 Common stock, 2,985.0 shares authorized, $0.01 par value per share;  



 shares issued: 809.6 and 690.7, respectively; 




 shares outstanding: 809.6 and 484.6, respectively 

8.1


6.9

 Additional paid-in capital 

21,156.1


2,438.2

 Accumulated other comprehensive income 

16.6


17.0

 Retained earnings 

1,564.1


6,645.6


22,744.9


9,107.7





 Common stock in treasury at cost, zero and 206.1 shares, respectively 

-


(6,634.0)

    Total stockholders' equity 

22,744.9


2,473.7

    Total liabilities and stockholders' equity 

$        57,307.7


$     15,607.0









 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Cash Flows 


 Nine Months Ended

September 30, 

 (in millions) 

2012


2011





 Cash flows from operating activities: 




 Net income  

$     808.8


$    985.4

 Adjustments to reconcile net income to net cash provided by operating activities: 




 Depreciation and amortization 

1,292.0


187.5

 Non-cash adjustments to net income 

37.8


152.9

 Deferred financing fees 

32.1


44.9

 Changes in operating assets and liabilities, net of effects of acquisition:  




 Accounts receivable 

382.6


(58.1)

 Claims and rebates payable 

(647.2)


44.4

 Other net changes in operating assets and liabilities 

143.3


302.9

 Net cash flows provided by operating activities 

2,049.4


1,659.9





 Cash flows from investing activities: 




 Acquisition of business, net of cash acquired 

(10,283.6)


-

 Purchases of property and equipment 

(106.0)


(98.1)

 Proceeds from sale of business 

31.5


-

 Other 

(16.2)


8.5

 Net cash used in investing activities 

(10,374.3)


(89.6)





 Cash flows from financing activities: 




 Proceeds from long-term debt, net of discounts 

7,458.9


1,494.0

 Repayment of long-term debt 

(2,710.6)


(0.1)

 Proceeds (repayment) of revolving credit line, net 

(1,000.0)


-

 Proceeds from accounts receivable financing facility 

600.0


-

 Repayment of accounts receivable financing facility 

(601.3)


-

 Excess tax benefit relating to employee stock compensation 

30.4


27.3

 Net proceeds from employee stock plans 

276.5


28.9

 Deferred financing fees 

(103.2)


(62.7)

 Treasury stock acquired 

-


(2,515.7)

 Net cash provided by (used in) financing activities 

3,950.7


(1,028.3)





 Effect of foreign currency translation adjustment 

2.5


(3.1)





 Net (decrease) increase in cash and cash equivalents 

(4,371.7)


538.9

 Cash and cash equivalents at beginning of period 

5,620.1


523.7

 Cash and cash equivalents at end of period 

$  1,248.4


$ 1,062.6









Table 1

Express Scripts Holding Company Unaudited Consolidated Selected Information

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,

Claims Volume

2012


2011


2012


2011

Network

282.9


147.2


721.5


444.0

Home delivery and specialty(1)

39.8


13.3


94.5


39.9

  Total claims

322.7


160.5


816.0


483.9









Total adjusted claims(2)

398.9


184.8


996.0


556.6









Depreciation and Amortization (D&A):








Revenue amortization(3)

$ 28.5


$ 28.5


$ 85.5


$ 85.5

Cost of revenues depreciation

39.4


9.6


76.5


31.2

Selling, general and administrative depreciation

47.9


13.1


121.7


40.3

Selling, general and administrative amortization

506.0


10.1


1,008.3


30.5

  Total D&A

$ 621.8


$ 61.3


$ 1,292.0


$ 187.5









Generic Fill Rate








Network

79.7%


75.3%


78.9%


75.2%

Home delivery

72.2%


63.0%


70.6%


62.5%

Overall

78.8%


74.1%


78.0%


74.0%









Note: See Appendix for footnotes.










Table 2

Calculation of Express Scripts Holding Company Adjusted Gross Profit and SG&A

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011

Gross profit, as reported

$ 2,134.5


$ 835.8


$ 5,079.4


$ 2,365.4

Amortization of legacy Express Scripts intangible assets (3)

28.5


28.5


85.5


85.5

Non-recurring transaction and integration costs (4)

21.8


-


33.7


-

Adjusted gross profit

$ 2,184.8


$ 864.3


$ 5,198.6


$ 2,450.9









Selling, general and administrative, as reported

$ 1,336.0


$ 230.7


$ 3,220.7


$ 628.6

Amortization of legacy Express Scripts intangible assets (3)

10.1


10.1


30.5


30.5

Amortization of Medco-related intangible assets (5)

495.9


-


977.8


-

Non-recurring transaction and integration costs (4)

179.1


20.3


586.1


20.3

Adjusted selling, general and administrative

$  650.9


$  200.3


$ 1,626.3


$  577.8









Note: See Appendix for footnotes.
















The Company is providing adjusted gross profit and selling, general and administrative expenses excluding the impact of non-recurring charges and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 3

Express Scripts Holding Company EBITDA Reconciliation

(in millions, except per claim data)

 

The following is a reconciliation of net income to EBITDA(6). The Company believes net income is the most directly comparable measure calculated under U.S. GAAP.

 


Three Months Ended

September 30,


Nine Months Ended

September 30,



2012


2011


2012


2011


Net income, as reported

$    391.4


$  324.7


$   808.8


$    985.4


  Provision for income taxes

257.7


192.0


602.2


574.9


  Depreciation and amortization

621.8


61.3


1,292.0


187.5


  Interest expense, net

154.5


88.4


457.1


176.5


  Undistributed gain from joint venture

(5.1)


-


(9.4)


-


EBITDA, as reported

1,420.3


666.4


3,150.7


1,924.3


Non-recurring transaction and integration costs (4)

200.9


20.3


619.8


20.3


Adjusted EBITDA

$ 1,621.2


$ 686.7


$ 3,770.5


$ 1,944.6











Total adjusted claims

398.9


184.8


996.0


556.6











Adjusted EBITDA per adjusted claim

$      4.06


$   3.72


$      3.79


$      3.49











Note: See Appendix for footnotes.


















The Company is providing EBITDA excluding the impact of non-recurring charges in order to compare the underlying financial performance to prior periods.

 

Table 4

Calculation of Express Scripts Holding Company Adjusted EPS










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011


(per diluted share)

EPS, as reported

$ 0.47


$ 0.66


$ 1.13


$ 1.93









Non-recurring/transaction-related items:








Transaction and integration costs (4)

0.15


0.03


0.51


0.03

Medco acquisition pre-close financing costs (7)

-


0.05


0.07


0.05

Discrete tax items (8)

-


-


0.06


-









Amortization of:








Legacy Express Scripts intangible assets(3)

0.03


0.05


0.10


0.14

Medco-related intangible assets(5)

0.37


-


0.81


-









EPS, adjusted

$ 1.02


$ 0.79


$ 2.68


$ 2.15









Note: See Appendix for footnotes.
















The Company is providing diluted earnings per share excluding the impact of non-recurring / transaction-related items and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 5

2012 Guidance Information


Estimated

Year Ended

December 31, 2012


(per diluted share)





Revised adjusted EPS guidance

$ 3.65

to

$ 3.75





GAAP items not included in guidance:








Amortization of legacy Express Scripts intangible assets

$0.12



Amortization of Medco-related intangible assets (9)

$1.19





Transaction and integration costs(10)

To be determined





The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range. 





 Note: See Appendix for footnotes.  












 Appendix 

 Footnotes 


(1)Includes home delivery, specialty and other including:  (a) drugs distributed through patient assistance programs (b) drugs we distribute to other PBMs' clients under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims. 


(2) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims. 


(3) Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense. Revenue amortization is related to the customer contract with WellPoint which consummated upon closing of the NextRx acquisition in 2009.  Under U.S. GAAP standards, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues.  Intangible amortization of $28.5 million ($17.6 million and $17.9 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the three months ended September 30, 2012 and 2011.   Intangible amortization of $85.5 million ($51.2 million and $54.0 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the nine months ended September 30, 2012 and 2011.  


In addition, intangible amortization of $10.1 million ($6.3 million net of tax) is included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011. Intangible amortization of $30.5 million ($18.3 million and $19.3 million net of tax in 2012 and 2011, respectively) is included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011.


(4) Non-recurring transaction and integration costs include those directly related to the acquisition of Medco Health Solutions, Inc. ("Medco").   


Costs of $21.8 million ($13.5 million net of tax) and $33.7 million ($20.2 million net of tax) for the three months and nine months ended September 30, 2012, respectively, primarily composed of integration-related activities, are included in cost of revenues.


Costs of $158.9 million ($98.4 million net of tax) and $20.3 million ($12.8 million net of tax) primarily composed of severance costs, including stock compensation, are included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011, respectively. Costs of $565.9 million ($339.0 million net of tax) and $20.3 million ($12.8 million net of tax) are included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011, respectively.


The Company recorded net charges of $20.2 million ($12.5 million and $12.1 million net of tax in the three months and nine months, respectively) within selling, general and administrative expenses for the three months and nine months ended September 30, 2012 in conjunction with the strategic decision to exit various businesses.


(5) Amortization of intangible assets related to the acquisition of Medco of $495.9 million ($307.0 million net of tax) and $977.8 million ($585.7 million net of tax) for the three months and nine months ended September 30, 2012, respectively is included in selling, general and administrative expense. 


(6)EBITDA is earnings before taxes, depreciation and amortization, net interest and other income (expense); or alternatively calculated as operating income plus depreciation and amortization.  EBITDA is presented because it is a widely accepted indicator of a company's ability to service indebtedness and is frequently used to evaluate a company's performance.  EBITDA, however, should not be considered as an alternative to net income, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with U.S. GAAP. In addition, this definition and calculation of EBITDA may not be comparable to that used by other companies.


(7)Financing costs include fees related to the amortization of remaining bridge loan fees, commitment fees related to the new credit agreement and interest and fees on the senior notes secured in conjunction with the acquisition of Medco.  Costs of $42.0 million ($26.4 million net of tax) are included interest expense in the three months ended September 30, 2011.  Costs of $85.2 million ($51.0 million net of tax) and $42.0 million ($26.5 million net of tax) are included in interest expense in the nine months ended September 30, 2012 and 2011, respectively. 


(8)Provision for income taxes includes discrete tax items of $43.5 million for the nine months ended September 30, 2012. These items primarily relate to adjustments to prior year income tax return filings and a reversal of the deferred tax asset previously established for transaction-related costs that became nondeductible upon the consummation of the Merger.  


(9) Adjusted EPS will exclude amortization of Medco-related intangible assets.  The current estimate of full year amortization based on the preliminary purchase price allocation.  The preliminary purchase price allocation may be subject to further refinement and may result in significant changes.  


(10) Adjusted EPS will exclude Medco-related transaction and integration costs. The full-year impact of these costs have yet to be determined. 

 

SOURCE Express Scripts

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
SYS-CON Events announced today that Ericsson has been named “Gold Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. Ericsson is a world leader in the rapidly changing environment of communications technology – providing equipment, software and services to enable transformation through mobility. Some 40 percent of global mobile traffic runs through networks we have supplied. More than 1 billion subscribers around the world re...
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
The increasing popularity of the Internet of Things necessitates that our physical and cognitive relationship with wearable technology will change rapidly in the near future. This advent means logging has become a thing of the past. Before, it was on us to track our own data, but now that data is automatically available. What does this mean for mHealth and the "connected" body? In her session at @ThingsExpo, Lisa Calkins, CEO and co-founder of Amadeus Consulting, will discuss the impact of wea...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
The IoTs will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm and share the must-have mindsets for removing complexity from the development proc...
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Increasing IoT connectivity is forcing enterprises to find elegant solutions to organize and visualize all incoming data from these connected devices with re-configurable dashboard widgets to effectively allow rapid decision-making for everything from immediate actions in tactical situations to strategic analysis and reporting. In his session at 18th Cloud Expo, Shikhir Singh, Senior Developer Relations Manager at Sencha, will discuss how to create HTML5 dashboards that interact with IoT devic...
Artificial Intelligence has the potential to massively disrupt IoT. In his session at 18th Cloud Expo, AJ Abdallat, CEO of Beyond AI, will discuss what the five main drivers are in Artificial Intelligence that could shape the future of the Internet of Things. AJ Abdallat is CEO of Beyond AI. He has over 20 years of management experience in the fields of artificial intelligence, sensors, instruments, devices and software for telecommunications, life sciences, environmental monitoring, process...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
You deployed your app with the Bluemix PaaS and it's gaining some serious traction, so it's time to make some tweaks. Did you design your application in a way that it can scale in the cloud? Were you even thinking about the cloud when you built the app? If not, chances are your app is going to break. Check out this webcast to learn various techniques for designing applications that will scale successfully in Bluemix, for the confidence you need to take your apps to the next level and beyond.
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry's single source for the cloud. Fusion's advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud...
Digital payments using wearable devices such as smart watches, fitness trackers, and payment wristbands are an increasing area of focus for industry participants, and consumer acceptance from early trials and deployments has encouraged some of the biggest names in technology and banking to continue their push to drive growth in this nascent market. Wearable payment systems may utilize near field communication (NFC), radio frequency identification (RFID), or quick response (QR) codes and barcodes...
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, will discuss how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technol...
We’ve worked with dozens of early adopters across numerous industries and will debunk common misperceptions, which starts with understanding that many of the connected products we’ll use over the next 5 years are already products, they’re just not yet connected. With an IoT product, time-in-market provides much more essential feedback than ever before. Innovation comes from what you do with the data that the connected product provides in order to enhance the customer experience and optimize busi...
SYS-CON Events announced today that Stratoscale, the software company developing the next generation data center operating system, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere...
Angular 2 is a complete re-write of the popular framework AngularJS. Programming in Angular 2 is greatly simplified – now it's a component-based well-performing framework. This immersive one-day workshop at 18th Cloud Expo, led by Yakov Fain, a Java Champion and a co-founder of the IT consultancy Farata Systems and the product company SuranceBay, will provide you with everything you wanted to know about Angular 2.
SYS-CON Events announced today that Men & Mice, the leading global provider of DNS, DHCP and IP address management overlay solutions, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. The Men & Mice Suite overlay solution is already known for its powerful application in heterogeneous operating environments, enabling enterprises to scale without fuss. Building on a solid range of diverse platform support,...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...